Although bladder cancer ranks as the sixth most common cancer in the United States, with approximately 85,000 new cases diagnosed each year, it continues to receive limited awareness, advocacy, and ...
SurvivorNet on MSN
Diagnosing muscle-invasive bladder cancer: The initial work-up
When a doctor suspects bladder cancer, they will order a series of tests which may include urine tests (urinalysis or urine ...
A combination of Merck’s Keytruda and Pfizer’s Padcev could offer a chemotherapy-free treatment alternative for patients with ...
Bladder cancer is the fourth most commonly diagnosed cancer in men in the United States and the 10th leading cause of cancer deaths. Many treatments can be used for bladder cancer, and the kind of ...
To further complicate clinicians’ treatment decisions, Padcev-Keytruda has become the new standard of care in first-line metastatic bladder cancer, raising the possibility that some physicians might ...
Chemotherapy uses medicines to kill fast-growing cells (like cancer cells) or to keep them from dividing (which is how cancers grow). It is a systemic treatment. This means the medicines will travel ...
SurvivorNet on MSN
A breakthrough for muscle-invasive bladder cancer: Padcev plus Keytruda drug combo could transform treatment around surgery
Nearly 200,000 Americans are living with muscle-invasive bladder cancer (MIBC)—and after decades with few major advances, newly presented data may signal a turning point in how the disease is treated.
Bladder cancer is a common cancer and one of the most costly to treat, yet there has been little change in the standard of care in 40 years. This panel will focus on the unmet needs in bladder cancer ...
Most people with bladder cancer begin treatment by having surgery to remove their cancer. If bladder cancer has spread beyond your bladder, you might have chemotherapy first. This can help treat ...
More than three decades ago, the U.S. Food and Drug Administration (FDA) approved Bacillus Calmette-Guérin (BCG) as the first immunotherapy against cancer. And it is still used today to treat ...
ImmunityBio (NasdaqGS:IBRX) completed enrollment early in its pivotal Phase 2 bladder cancer trial for ANKTIVA. Interim analysis showed a statistically significant improvement in complete response ...
When you learn you have bladder cancer, it’s only natural to ask: "Can I survive this, for how long, and can I expect to be cured?" You may have searched online for survival rate information. These ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results